Proof of concept evaluation of a novel breast cancer therapeutic
206,547
2022-05-01 to 2023-11-30
Collaborative R&D
Recent research has suggested that the over activation of a receptor on the surface of cancer cells, called the angiotensin-II type I receptor (AT1R), triggers biological signalling pathways that play a role in many cancer-related processes including tumour growth, angiogenesis, drug resistance and metastasis.
aTen Therapeutics is developing a novel therapeutic antibody that targets and blocks cancer-related signalling mediated by the AT1R in order to treat breast cancer. This project is a vital step in the development of an innovative breast cancer therapy with the potential to become a major new drug to improve the quality and duration of patients' lives.
Get notified when we’re launching.
Want fast, powerful sales prospecting for UK companies? Signup below to find out when we're live.